-
1
Study explores AI's role in treatment decisions for macular disease.
-
2
374 participants were surveyed, with 181 fully completing the task.
-
3
Key factors influencing trust were error rates and second checks.
-
4
Patients care more about reliability than who makes decisions.
-
5
AI acceptance in clinics requires focus on performance and transparency.
-
The Eye Open study by the Macular Society investigates patient acceptance of AI in treatment decisions for macular disease, particularly in retreatment scenarios. Using conjoint analysis, researchers assessed factors influencing patient trust, involving 374 participants with varying degrees of AMD. Key findings revealed that patients prioritized error rates and the presence of second checkers over the identity of the first reader, whether human or AI. The results signal a need for ophthalmology to focus on performance, reliability, and transparency in AI applications.
-
1
Study explores AI's role in treatment decisions for macular disease.
-
2
374 participants were surveyed, with 181 fully completing the task.
-
3
Key factors influencing trust were error rates and second checks.
-
4
Patients care more about reliability than who makes decisions.
-
5
AI acceptance in clinics requires focus on performance and transparency.
Listen Tab content
